Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 50 of 1447 for:    prostate cancer AND radiation

Oral Docetaxel (ModraDoc/r) in Combination With Hormonal Treatment and Radiation Therapy in High-risk Prostate Cancer (DOP)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03066154
Recruitment Status : Recruiting
First Posted : February 28, 2017
Last Update Posted : February 28, 2017
Sponsor:
Information provided by (Responsible Party):
The Netherlands Cancer Institute

Brief Summary:

The optimal treatment for HRPC patients has not yet been established. Recent trials suggest a benefit from early treatment with docetaxel in the castration-sensitive setting, with an improvement in failure free survival in high risk and metastatic patients and increase in overall survival in the metastatic hormone-sensitive group. In these recent randomized controlled trials, patients were treated with hormonal therapy and radiotherapy and adjuvant docetaxel, assuming that early systemic treatment for high risk or metastatic disease could delay progression in patients with aggressive primary tumor characteristics.

With the fact that docetaxel is a known radiosensitizer, combined modality treatment with docetaxel during the radiotherapy could also lead to better local control and reduction of local recurrence. Several phase I and II studies have been done in HRPC patients, to evaluate the combination of high dose radiotherapy and concurrent weekly infusions with docetaxel.

Oral administration of docetaxel has many advantages above intravenously administered drugs for patients. Besides the higher patient convenience, possibly longer treatment duration can be achieved due to better safety. Frequently occurring toxicities of intravenously administered docetaxel, such as neutropenia, hypersensitivity reactions and peripheral polyneuropathy have rarely been observed with the oral docetaxel formulation ModraDoc006/r.

The primary aim of the N15DOP study is to determine the maximum tolerable dose (MTD) of ModraDoc006/r when given in a weekly bidaily schedule in combined modality with high dose intensity radiotherapy and hormonal therapy in castration-sensitive prostate cancer patients with high risk disease, including positive lymph nodes.


Condition or disease Intervention/treatment Phase
Prostatic Neoplasms Drug: oral docetaxel (ModraDoc/r) Drug: androgen deprivation therapy Radiation: high-dose intensity-modulated radiation therapy Phase 1

Detailed Description:

Phase IA part This is an open-label, dose-escalating, non-randomized, single centre phase I study of ModraDoc006/r combined with ADT and radiotherapy in patients with high risk prostate cancer, as defined by node positive prostate cancer with all of the following primary tumor characteristics: stage ≥cT2c, Gleason score ≥ 4+3, any PSA level.

Phase IB part After determination of the MTD of ModraDoc006/r in the combined treatment with radiotherapy and hormonal therapy and good tolerability of the treatment without unexpected adverse events during the radiotherapy until 6 weeks after the end of radiotherapy, the study will be further conducted to the phase IB part. This part will explore the feasibility and tolerability of long term treatment with ModraDoc006/r.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 24 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Weekly ModraDoc/r in Combination With Hormonal Treatment and High-dose Intensity-modulated Radiation Therapy in Patients With High-risk Early Stage Prostate Cancer
Study Start Date : September 2016
Estimated Primary Completion Date : September 2019
Estimated Study Completion Date : January 2020

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Prostate Cancer
Drug Information available for: Docetaxel

Arm Intervention/treatment
Experimental: N15DOP
Chemoradiation with ModraDoc/r and radiotherapy of the prostate in dose escalation design, followed by maintenance treatment.
Drug: oral docetaxel (ModraDoc/r)
Weekly once- or twice daily ModraDoc/r
Other Name: ModraDoc006/ritonavir

Drug: androgen deprivation therapy
ADT according to the standard of care
Other Name: hormonal therapy

Radiation: high-dose intensity-modulated radiation therapy
77 Gy in 35 fractions of 2.2 Gy, 5 fractions a week
Other Name: radiotherapy




Primary Outcome Measures :
  1. Maximal tolerated dose (MTD) of ModraDoc/r in the combination treatment [ Time Frame: 12 months ]
    MTD of ModraDoc006/r (as ModraDoc006 10 mg tablets in combination with one tablet of 100 mg ritonavir) that can safely be administered in a bi-daily weekly schedule in combination with high-dose intensity modulated radiation therapy and androgen-deprivation therapy


Secondary Outcome Measures :
  1. Number of participants with treatment-related adverse events as assessed by CTCAE v.4.03 with treatment with ModraDoc006/r in combination with ADT and high dose radiotherapy [ Time Frame: 12 months ]
  2. Number of patients that will have recurrence of prostate cancer after completion of the study treatment [ Time Frame: 10 years ]
  3. To determine the Peak Plasma Concentration (Cmax) of docetaxel in this regime. [ Time Frame: 12 months ]
  4. To determine the "Area under the plasma concentration versus time curve (AUC) of docetaxel in this regime. [ Time Frame: 12 months ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Histologically proven prostate cancer.
  2. All eligible patients have hormone naïve non-metastatic node positive high risk prostate cancer. Node positive cancer will be defined as radiological demonstration of more than four pelvic lymph node(s) consisting of bean shaped lymph node(s) with a short axis of minimal 10 mm and/or round lymph node(s) with a minimal size of 8 mm on PSMA, MRI or CT scan.

    PSMA-scans or PET-Choline scans may be used, but are not obligated. Since the use of the PSMA scan is significantly increased in current clinical practice and the chance of false positive results is considered very low in patients with more than 4 positive lymph nodes, histological confirmation of positive lymph nodes is not required for inclusion if more than 4 pathological nodes are seen with the PSMA, MRI or CT scan

  3. High risk prostate cancer will be defined as node positive with all of the following primary tumour characteristics: Tumour stage ≥cT2c and Gleason score ≥4+3, any PSA
  4. Age ≥ 18 years
  5. No signs of metastatic disease on standard diagnostic scans.
  6. Normal serum testosterone levels prior to treatment
  7. Adequate haematological, renal and hepatic functions

    1. Haemoglobin ≥ 6.0 mmol/l
    2. ANC of ≥ 1.5 x 109 /L
    3. Platelet count of ≥ 100 x 109 /L
    4. Hepatic function as defined by serum bilirubin ≤ 1.5 x ULN, ALAT and ASAT ≤ 2.5 x ULN
    5. Renal function as defined by serum creatinine ≤ 1.5 x ULN or creatinine clearance ≥ 50 ml/min (by Cockcroft-Gault formula).
  8. WHO performance status of 0-2
  9. Able and willing to undergo blood sampling for PK and PD analysis;
  10. Life expectancy ≥ 3 months allowing adequate follow up of toxicity evaluation and antitumor activity;
  11. Able and willing to swallow oral medication
  12. Able and willing to give written informed consent;

Exclusion Criteria:

  1. Any treatment with investigational drugs, chemotherapy or immunotherapy within 30 days prior to receiving the first dose of investigational treatment; Patients may be on ADT as long as this is has not been longer than 4 weeks prior the start of the radiotherapy.
  2. Patients who have had prior pelvic radiation therapy
  3. Patients who have had prior treatment with taxanes
  4. TURP within 3 months before start of the study
  5. Patients who have had a prostatectomy.
  6. Any contra-indication for MRI
  7. Major difficulties for marker implantation
  8. Unreliable contraceptive methods. Men enrolled in this trial must agree to use a reliable contraceptive method throughout the study (adequate contraceptive methods are: condom, sterilization)
  9. Unresolved (> grade 1) toxicities of previous chemotherapy, excluding alopecia.
  10. Uncontrolled infectious disease or known Human Immunodeficiency Virus HIV-1 or HIV-2 type patients;
  11. Patients with a known history of hepatitis B or C;
  12. Bowel obstructions or motility disorders that may influence the resorption of drugs as judged by the treating physician
  13. Concomitant use of MDR and CYP3A modulating drugs such as Ca+- entry blockers (verapamil, dihydropyridines), cyclosporine, quinidine, tamoxifen, megestrol and grapefruit juice, concomitant use of HIV medications, other protease inhibitors, (non) nucleoside analoga, or St. John's wort.
  14. Pre-existing neuropathy greater than NCI-CTCAE v4.03 grade 1.
  15. Patients with known alcoholism, drug addiction and/or psychiatric of physiological condition which in the opinion of the investigator would impair study compliance; Evidence of any other disease, neurological or metabolic dysfunction, physical examination finding or laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug or puts the patient at high risk for treatment-related complications.
  16. Legal incapacity

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03066154


Contacts
Layout table for location contacts
Contact: B van Triest, MD, PhD 0205129111 b.v.triest@nki.nl
Contact: M Vermunt, MD 0205122127 m.vermunt@nki.nl

Locations
Layout table for location information
Netherlands
Netherlands Cancer Institute Recruiting
Amsterdam, Netherlands
Contact: B van Triest, MD, PhD    0205129111    b.v.triest@nki.nl   
Contact: M Vermunt, MD    0205122127    m.vermunt@nki.nl   
Sponsors and Collaborators
The Netherlands Cancer Institute
Investigators
Layout table for investigator information
Principal Investigator: B van Triest, MD, PhD The Netherlands Cancer Institute

Layout table for additonal information
Responsible Party: The Netherlands Cancer Institute
ClinicalTrials.gov Identifier: NCT03066154     History of Changes
Other Study ID Numbers: N15DOP
First Posted: February 28, 2017    Key Record Dates
Last Update Posted: February 28, 2017
Last Verified: February 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by The Netherlands Cancer Institute:
High risk prostate cancer
>T2cN+M0
Additional relevant MeSH terms:
Layout table for MeSH terms
Prostatic Neoplasms
Genital Neoplasms, Male
Urogenital Neoplasms
Neoplasms by Site
Neoplasms
Prostatic Diseases
Genital Diseases, Male
Docetaxel
Androgens
Antineoplastic Agents
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs